US FDA approval of Pfizer Inc.'s Xeljanz in psoriatic arthritis does not appear to be in much doubt going forward, but whether radiographic progression information will appear in labeling could be a point of contention.
FDA's Arthritis Advisory Committee on Aug. 3 voted 10-1 to recommend approval of the new indication for Xeljanz (tofacitinib) and...